Dannielle Appelhans
Directeur/Bestuurslid bij GENERATION BIO CO.
Vermogen: 60 200 $ op 30-04-2024
Actieve functies van Dannielle Appelhans
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| GENERATION BIO CO. | Directeur/Bestuurslid | 15-07-2022 | - |
Cour Pharmaceuticals Development Co., Inc.
 Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Operationeel Directeur | 19-07-2023 | - |
Loopbaan van Dannielle Appelhans
Eerdere bekende functies van Dannielle Appelhans
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| RUBIUS THERAPEUTICS | Algemeen Directeur | 15-11-2022 | 03-03-2023 |
| Operationeel Directeur | 09-08-2021 | 15-11-2022 | |
| President | 15-11-2022 | 03-03-2023 | |
| AVEXIS INC | Hoofd Techniek/Wetenschap/O&O | 01-01-2020 | 01-01-2021 |
Opleiding van Dannielle Appelhans
| MIT Sloan School of Management | Masters Business Admin |
| University of Michigan | Undergraduate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 8 |
Operationeel
| Chief Operating Officer | 2 |
| Chief Executive Officer | 1 |
| President | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GENERATION BIO CO. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Cour Pharmaceuticals Development Co., Inc.
Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Health Technology |
- Beurs
- Insiders
- Dannielle Appelhans
- Ervaring
